<?xml version="1.0" encoding="UTF-8"?>
<p id="p0055">The Breakthrough Therapy designation directs the expedited development and review of products that can provide substantial improvement over available therapy, which expands the benefits that patients experience over prior treatments.
 <xref rid="bib19" ref-type="bibr">
  <sup>19</sup>
 </xref> Products approved in 2020 that were granted a Breakthrough Therapy designation include avapritinib for patients with gastrointestinal stromal tumor, and nintedanib for patients with chronic fibrosing interstitial lung diseases. There was a cumulative total of 156 approvals for all products given the Breakthrough Therapy designation by CDER through December 2019.
 <xref rid="bib20" ref-type="bibr">
  <sup>20</sup>
 </xref>
</p>
